{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:36:52Z","timestamp":1769121412629,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The population representativeness of a clinical study is influenced by how real-world patients qualify for the study. We analyze the representativeness of eligible patients for multiple type 2 diabetes trials and the relationship between representativeness and other trial characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Sixty-nine study traits available in the electronic health record data for 2034 patients with type 2 diabetes were used to profile the target patients for type 2 diabetes trials. A set of 1691 type 2 diabetes trials was identified from ClinicalTrials.gov, and their population representativeness was calculated using the published Generalizability Index of Study Traits 2.0 metric. The relationships between population representativeness and number of traits and between trial duration and trial metadata were statistically analyzed. A focused analysis with only phase 2 and 3 interventional trials was also conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 869 of 1691 trials (51.4%) and 412 of 776 phase 2 and 3 interventional trials (53.1%) had a population representativeness of &amp;lt;5%. The overall representativeness was significantly correlated with the representativeness of the Hba1c criterion. The greater the number of criteria or the shorter the trial, the less the representativeness. Among the trial metadata, phase, recruitment status, and start year were found to have a statistically significant effect on population representativeness. For phase 2 and 3 interventional trials, only start year was significantly associated with representativeness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study quantified the representativeness of multiple type 2 diabetes trials. The common low representativeness of type 2 diabetes trials could be attributed to specific study design requirements of trials or safety concerns. Rather than criticizing the low representativeness, we contribute a method for increasing the transparency of the representativeness of clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jamia\/ocx091","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T19:12:15Z","timestamp":1502305935000},"page":"239-247","source":"Crossref","is-referenced-by-count":14,"title":["The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0"],"prefix":"10.1093","volume":"25","author":[{"given":"Anando","family":"Sen","sequence":"first","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Chakrabarti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Yaman","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Computer Science, Eindhoven University of Technology, Eindhoven, Netherlands,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"},{"name":"Janssen Research and Development, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"key":"2020110612234586400_ocx091-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials."},{"key":"2020110612234586400_ocx091-B2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jbi.2016.01.007","article-title":"Multivariate analysis of the population representativeness of related clinical studies","volume":"60","author":"He","year":"2016","journal-title":"J Biomed Inform."},{"key":"2020110612234586400_ocx091-B3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/CIRCOUTCOMES.113.000418","article-title":"Representativeness of RELAX-AHF clinical trial population in acute heart failure","volume":"7","author":"Wang","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"2020110612234586400_ocx091-B4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0002-8703(03)00189-3","article-title":"Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure","volume":"146","author":"Masoudi","year":"2003","journal-title":"Am Heart J."},{"key":"2020110612234586400_ocx091-B5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/nyas.13195","article-title":"Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials","volume":"1387","author":"Sen","year":"2017","journal-title":"Ann NY Acad Sci."},{"key":"2020110612234586400_ocx091-B6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4338\/ACI-2013-12-RA-0105","article-title":"A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records","volume":"5","author":"Weng","year":"2014","journal-title":"Appl Clin Inform."},{"key":"2020110612234586400_ocx091-B7","first-page":"291","article-title":"Knowledge engineering for a clinical trial advice system: Uncovering errors in protocol specification","volume":"74","author":"Musen","year":"1987","journal-title":"Bull Cancer."},{"key":"2020110612234586400_ocx091-B8","first-page":"46","article-title":"Analysis of eligibility criteria complexity in clinical trials","author":"Ross","year":"2010","journal-title":"AMIA Summits Transl Sci Proc"},{"key":"2020110612234586400_ocx091-B9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbi.2014.01.009","article-title":"Clustering clinical trials with similar eligibility criteria features","volume":"52","author":"Hao","year":"2014","journal-title":"J Biomed Inform."},{"key":"2020110612234586400_ocx091-B10","first-page":"724","article-title":"Knowledge representation and tool support for critiquing clinical trial protocols","author":"Rubin","year":"2000","journal-title":"Proc AMIA Annu Symp."},{"key":"2020110612234586400_ocx091-B11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.tips.2015.08.007","article-title":"Optimizing clinical research participant selection with informatics","volume":"36","author":"Weng","year":"2015","journal-title":"Trends Pharmacol Sci."},{"key":"2020110612234586400_ocx091-B12","first-page":"67","article-title":"Multivariate analysis of the population representativeness of related clinical studies","volume":"60","author":"He","year":"2016"},{"key":"2020110612234586400_ocx091-B13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.2106\/JBJS.M.00531","article-title":"Lack of diversity in orthopaedic trials conducted in the United States","volume":"96","author":"Somerson","year":"2014","journal-title":"J Bone Joint Surg Am."},{"key":"2020110612234586400_ocx091-B14","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1474-4422(04)00884-1","article-title":"The age gap between patients in clinical studies and in the general population: a pitfall for dementia research","volume":"3","author":"Schoenmaker","year":"2004","journal-title":"Lancet Neurol."},{"key":"2020110612234586400_ocx091-B15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4088\/JCP.12m07935","article-title":"Generalizability of clinical trial results for bipolar disorder to community samples","volume":"74","author":"Hoertel","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"2020110612234586400_ocx091-B16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jbi.2016.09.003","article-title":"GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies","volume":"63","author":"Sen","year":"2016","journal-title":"J Biomed Inform."},{"key":"2020110612234586400_ocx091-B17","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1002\/sim.5802","article-title":"The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias","volume":"32","author":"Pressler","year":"2013","journal-title":"Stat Med."},{"key":"2020110612234586400_ocx091-B18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/sim.3218","article-title":"Generalizing from clinical trial data: A case study. The risk of suicidality among pediatric antidepressant users","volume":"27","author":"Greenhouse","year":"2008","journal-title":"Stat Med."},{"key":"2020110612234586400_ocx091-B19","doi-asserted-by":"crossref","first-page":"i116","DOI":"10.1136\/amiajnl-2011-000321","article-title":"EliXR: an approach to eligibility criteria extraction and representation","volume":"18 (Suppl 1)","author":"Weng","year":"2011","journal-title":"J Am Med Inform Assoc."},{"key":"2020110612234586400_ocx091-B20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3414\/ME15-01-0112","article-title":"Valx: a system for extracting and structuring numeric lab test comparison statements from text","volume":"55","author":"Hao","year":"2016","journal-title":"Methods Inf Med."},{"key":"2020110612234586400_ocx091-B21","doi-asserted-by":"crossref","first-page":"ITC315","DOI":"10.7326\/0003-4819-152-5-201003020-01003","article-title":"Type 2 diabetes","volume":"152","author":"Vijan","year":"2010","journal-title":"Ann Intern Med."},{"key":"2020110612234586400_ocx091-B22","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1136\/amiajnl-2013-001926","article-title":"Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory","volume":"20","author":"Richesson","year":"2013","journal-title":"J Am Med Inform Assoc."},{"key":"2020110612234586400_ocx091-B23","first-page":"e121","article-title":"Assessing electronic health record phenotypes against gold-standard diagnostic criteria for diabetes mellitus","volume":"42","author":"Spratt","year":"2016","journal-title":"J Am Med Inform Assoc."},{"key":"2020110612234586400_ocx091-B24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jbi.2015.12.006","article-title":"Electronic health record phenotyping improves detection and screening of type 2 diabetes in the general United States population: a cross-sectional, unselected, retrospective study","volume":"60","author":"Anderson","year":"2016","journal-title":"J Biomed Inform."},{"key":"2020110612234586400_ocx091-B25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2288-14-75","article-title":"Tuning multiple imputation by predictive mean matching and local residual draws","volume":"14","author":"Morris","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"2020110612234586400_ocx091-B26","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2020110612234586400_ocx091-B27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/pharmaceutics5010094","article-title":"Safety monitoring in clinical trials","volume":"5","author":"Yao","year":"2013","journal-title":"Pharmaceutics."},{"key":"2020110612234586400_ocx091-B28","volume-title":"Safety Guidlines","author":"International Council for Harmonisation","year":"2016"},{"key":"2020110612234586400_ocx091-B29","volume-title":"Phases of Clinical Trials","author":"Cancer.Net Editorial Board","year":"2015"},{"key":"2020110612234586400_ocx091-B30","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.1996.14.4.1364","article-title":"Reducing patient eligibility criteria in cancer clinical trials","volume":"14","author":"George","year":"1996","journal-title":"J Clin Oncol."},{"key":"2020110612234586400_ocx091-B31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jacc.2015.10.037","article-title":"Generalizability of results from the Systolic Blood Pressure Intervention Trial (SPRINT) to the US adult population","volume":"67","author":"Bress","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"2020110612234586400_ocx091-B32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2229-3485.184820","article-title":"Challenges in recruitment and retention of clinical trial subjects","volume":"7","author":"Kadam","year":"2016","journal-title":"Perspect Clin Res."},{"key":"2020110612234586400_ocx091-B33","volume-title":"Facing the Challenges of Recruitment to Clinical Trials \u2013 Clinfield","author":"Gelling","year":"2016"},{"key":"2020110612234586400_ocx091-B34","first-page":"1808","article-title":"The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies","volume":"31(8)","author":"Statler","year":"2016","journal-title":"Leukemia."},{"key":"2020110612234586400_ocx091-B35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamainternmed.2014.6300","article-title":"Geographic accessibility to clinical trials for advanced cancer in the United States","volume":"175","author":"Galsky","year":"2015","journal-title":"JAMA Intern Med."},{"key":"2020110612234586400_ocx091-B36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/dme.12181","article-title":"The effects of patient characteristics and geographical region on hospitalization in patients with Type 2 diabetes","volume":"30","author":"Zaman","year":"2013","journal-title":"Diabet Med."},{"key":"2020110612234586400_ocx091-B37","article-title":"Why do recruitment efforts fail to enroll enough patients?","author":"Lopienski"},{"key":"2020110612234586400_ocx091-B38","first-page":"58","article-title":"Patient recruitment driving length and cost of oncology clinical trials","volume":"5","author":"Bianchi","year":"2013","journal-title":"Int Pharm Ind."},{"key":"2020110612234586400_ocx091-B39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med."},{"key":"2020110612234586400_ocx091-B40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.31887\/DCNS.2011.13.2\/npatsopoulos","article-title":"A pragmatic view on pragmatic trials","volume":"13","author":"Patsopoulos","year":"2011","journal-title":"Dialogues Clin Neurosci."},{"key":"2020110612234586400_ocx091-B41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2369-15-180","article-title":"Effects of the dual peroxisome proliferator-activated receptor-\u03b1\/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study","volume":"15","author":"Ruilope","year":"2014","journal-title":"BMC Nephrol."},{"key":"2020110612234586400_ocx091-B42","first-page":"1472","article-title":"Sick patients have more data: the non-random completeness of electronic health records","author":"Weiskopf","year":"2013","journal-title":"AMIA Annu Symp Proc."},{"key":"2020110612234586400_ocx091-B43","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/j.1475-6773.2005.00444.x","article-title":"Measuring diagnoses: ICD code accuracy","volume":"40","author":"O\u2019Malley","year":"2005","journal-title":"Health Serv Res."}],"container-title":["Journal of the American Medical Informatics Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/25\/3\/239\/34149887\/ocx091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jamia\/article-pdf\/25\/3\/239\/34149887\/ocx091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T17:29:51Z","timestamp":1604683791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jamia\/article\/25\/3\/239\/4157244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,13]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jamia\/ocx091","relation":{},"ISSN":["1067-5027","1527-974X"],"issn-type":[{"value":"1067-5027","type":"print"},{"value":"1527-974X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2017,9,13]]}}}